Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial

Metabolism: Clinical and Experimental

Volumn 58, Issue 3, 2009, Pages 393-400

  Zimering, Mark B ^a,b   Anderson, Robert J ^a,c   Moritz, Thomas E ^a   Ge, Ling ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL CELL ANTIBODY; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANIMAL CELL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETIC RETINOPATHY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREACTIVITY; LASER COAGULATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; ANIMALS; AUTOANTIBODIES; BLOOD PRESSURE; CATTLE; CELL COUNT; CHROMATOGRAPHY, AFFINITY; COLORIMETRY; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; LASER COAGULATION; MIDDLE AGED; PULMONARY ARTERY; STAPHYLOCOCCAL PROTEIN A;

EID: 59649085778     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.10.014     Document Type: Article

References (41)

1. Girach A., and Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract 61 (2007) 88-97
2. Aroca P.R., Salvat M., Fernandez J., and Mendez I. Risk factor for diffuse and focal macular edema. J Diabet Complications 18 (2004) 211-215
3. Grant M.B., Afzal A., Spoerri P., Pan H., Shaw L.C., and Mames R.N. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs (2004) 1275-1279
4. Aiello L.P., and Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77 (2000) S113-S119
5. Nguyen Q.D., Tatlipinar S., Shah S.M., Haller J.A., Quinlan E., Sung J., et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142 (2006) 961-969
6. Boulton M., Gregor Z., McLeod D., Charteris D., Jarvis-Evans J., Moriarty P., et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 81 (1997) 228-233
7. Gospodarowicz D., Ferrara N., Schweigerer L., and Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8 (1987) 95-114
8. Schweigerer L., Neufeld G., Friedman J., Abraham J.A., Fiddes J.C., and Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325 (1987) 257-259
9. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
10. Esch F., Baird A., Ling N., Ueno N., Hill F., Denoroy L., et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Nat Acad Sci U S A 19 (1985) 6507-6511
11. Zimering M.B., and Eng J. Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. J Clin Endo Metab 81 (1996) 4446-4452
12. Abraira C., Duckworth W., McCarren M., Emanuele N., Arca D., Reda D., et al. Design of the cooperative study of glycemic control and complications in diabetes mellitus type 2. J Diabet Complications 17 (2003) 314-322
13. Zimering M.B. Effect of intravenous bisphosphonates on release of basic fibroblast growth factor in serum of patients with cancer-associated hypercalcemia. Life Sci 70 (2002) 1-14
14. Larsson A., Skoldenberg E., and Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 5 (2002) 107-110
15. Higgins G.T., Khan J., and Pearce I.A. Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: what lessons have we learned from the UKPDS and DCCT studies?. Acta Ophthalmol Scand 85 (2007) 772-776
16. Miljanovic B., Glynn R.J., Nathan D.M., Manson J.E., and Schaumberg D.A. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 53 (2004) 2883-2892
17. Zimering M.B., and Thakker-Varia S. Increased fibroblast growth factor-like autoantibodies in serum from a subset of patients with cancer-associated hypercalcemia. Life Sci 71 (2002) 2939-2959
18. Zimering M.B., Brandi M.L., deGrange D.A., Marx S.J., Streeten E., Katsumata N., et al. Circulating fibroblast growth factor-like substance in familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 70 (1990) 149-154
19. Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351 (1998) 28-31
20. Sjølie A.K. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res Clin Pract 76 Suppl 1 (2007) S31-S39
21. Chaturvedi N., Fuller J.H., Pokras F., Rottiers R., Papazoglou N., Aiello L.P., et al. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med (2001) 288-294
22. Shimada K., Baba T., Neugebauer S., Onozaki A., Yamada D., Midorikawa S., et al. Plasma vascular endothelial growth factor in Japanese type 2 diabetic patients with and without nephropathy. J Diabetes Complications 16 (2002) 386-390
23. Cottone S., Vadalà A., Mangano M.T., Riccobene R., Vella M.C., Neri A.L., et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 13 (2000) 172-176
24. Teichert-Kuliszewska K., Hamilton B.S., Deitel M., and Roncari D.A. Augmented production of heparin-binding mitogenic proteins by preadipocytes from massively obese persons. J Clin Invest 90 (1992) 1226-1231
25. Lijnen P., Fagard R., Staessen J., and Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 12 (1981) 387-392
26. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
27. Dirix L.Y., Vermeulen P.B., Pawinski A., Prové A., Benoy I., De Pooter C., et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76 (1997) 238-243
28. Zimering M.B., Anderson R.J., Ge L., Moritz T., Pardun J., and the VADT Substudy Group. Association between endothelial cell inhibitory autoantibodies and laser treatment for retinopathy in a baseline subset from the Veterans Affairs Diabetes Trial. Endocr Soc OR50-4 (2008) 163
29. Vlodavsky I., Miao H.Q., Medalion B., Danagher P., and Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15 (1996) 177-186
30. Fillit H., and Lahita R. Antibodies to vascular heparan sulfate proteoglycan in patients with systemic lupus erythematosus. Autoimmunity 9 (1991) 159-164
31. Fillit H., and Mulvihill M. Association of autoimmunity to vascular heparan sulfate proteoglycan and vascular disease in the aged. Gerontology 39 (1993) 177-182
32. Reddi A.S., Ramamurthi R., Miller M., Dhuper S., and Lasker N. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 45 (1991) 119-131
33. Jensen T. Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes 46 Suppl 2 (1997) S98-S100
34. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., and Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32 (1989) 219-226
35. Jones D.B., Wallace R., and Frier B.M. Vascular endothelial cell antibodies in diabetic patients. Association with diabetic retinopathy. Diabetes Care 15 (1992) 552-555
36. Weiss A.G., Chacko D.M., Lane P.H., Margalit E., Thompson A.F., Mack-Shipman L.R., et al. Vascular endothelial growth factor, soluble vascular endothelial growth factor receptor-1, and progression of diabetic retinopathy in pregnant patients with type 1 diabetes. Endocr Soc (2007) P3-P160
37. Ferrara N., and Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161 (1989) 851-858
38. Pepper M.S., Ferrara N., Orci L., and Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189 (1992) 824-831
39. Hove M.N., Kristensen J.K., Lauritzen T., and Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol Scand 82 (2004) 443-448
40. Kempen J.H., O'Colmain B.J., Leske M.C., Haffner S.M., Klein R., Moss S.E., et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122 (2004) 552-563
41. Zhang L., Krzentowski G., Albert A., and Lefebvre P.J. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24 (2001) 1275-1279